|
|
|
PROTEIN KINASE C (PKC) SIGNALING PATHWAY (PW:0000840)
DescriptionThe protein kinase C family (PKC) comprises ~2% of the human kinome and can be subdivided into three subclasses: conventional or classical (cPKC), novel (nPKC) and atypical (aPKC). All isoforms contain a C-terminal kinase domain and an N-terminal autoinhibitory pseudosubstrate but differ in their responsiveness to second messengers. A tandem DAG-sensitive C1 domain is present in cPKC and nPKC with the latter group displaying a higher sensitivity. The C2 domain is Ca2+ sensitive in cPKC only. The single C1domain in aPKC is DAG-insensitive; this group depends on other lipids or protein-protein interactions for functional regulation. Collectively, the pathway regulates cell proliferation, differentiation, polarity and death and plays a role in the cardiac, immune and nervous systems. PKC signaling is initiated downstream of ligand-activated G protein coupled receptors (GPCR) that trigger the signal transduction mediated by the Galphaq family of heterotrimeric G proteins. The Galphaq activates the beta subtype of phospholipase C (PLC; PLC-B). Other PLC subtypes can be activated downstream of receptor tyrosine kinases (RTK) with potential role in PKC activation. PLC catalyzes the hydrolysis of PIP2 to produce DAG and IP3; IP3 promotes calcium release from ER. Newly synthesized PKCs need priming for maturation - a process that involves a series of tightly controlled phosphorylation events. The Hsp90 chaperone and Cdc37co-chaperone are required for the proper processing of cPKC and nPKCs. Pdpk1 phosphorylates the activation loop of PLC, an event that is constitutive for cPKC and nPKCs but agonist dependent for aPKCs. A second phosphorylation at the turn motif, completes the maturation of PKC and is dependent on mTORC2 complex. Whether the role of mTORC2 is direct or indirect, via activation of an upstream kinase, is currently unclear. Mature, fully phosphorylated PKCs are in the cytoplasm and bound to the autoinhibitory pseudosubstrate. Signals that release calcium facilitate recruitment to the plasma membrane followed by DAG binding or there is direct membrane recruitment via high DAG affinity. At the membrane, PKC is in an open conformation which promotes release of pseudosubstrate and binding of a variety of interactors - adaptors or scaffolds and other binding partners and substrates, in order to fulfill many cellular tasks. The open conformation can also promotes dephosphorylation by members of PPM phosphatase family. Dephosphorylated PKC is sequestered in insoluble fraction for further dephosphorylation and subsequent degradation. However, it can also be bound by HSP70 which promotes its re-phosphorylation and re-enter into the signaling cycle. Internalization of receptors and conversion of DAG to PA by DGKs terminates signaling (not shown). Deregulation of PKC signaling pathway has been implicated in tumorigenesis and neurodegeneration. To see the Ontology Report, for annotations, GViewer and download, click here[click to see the ontology report for related GO term - GO:0070528] ...(less)
|
Pathway Diagram:
|
|
|
Genes in Pathway:
protein kinase C (PKC) signaling pathway
|
| G |
Btk |
Bruton agammaglobulinemia tyrosine kinase |
|
|
ISS |
X |
121,998,935 |
122,030,289 |
RGD:5131492 |
RGD |
| G |
Cdc37 |
cell division cycle 37 |
|
|
ISS |
8 |
20,164,150 |
20,176,763 |
RGD:5131489 |
RGD |
| G |
Copb1 |
coatomer protein complex, subunit beta 1 |
|
|
ISS |
1 |
172,199,676 |
172,233,765 |
RGD:5131491 |
RGD |
| G |
Fscn1 |
fascin homolog 1, actin bundling protein (Strongylocentrotus purpuratus) |
|
|
ISS |
|
|
|
RGD:5131492 |
RGD |
| G |
Fyn |
FYN oncogene related to SRC, FGR, YES |
|
|
ISS |
20 |
43,501,853 |
43,695,567 |
RGD:5131492 |
RGD |
| G |
Gnb2l1 |
guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 |
|
|
ISS |
10 |
34,067,237 |
34,072,593 |
RGD:5131491 |
RGD |
| G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
|
|
ISS |
6 |
135,413,616 |
135,419,147 |
RGD:5131489 |
RGD |
| G |
Lck |
lymphocyte-specific protein tyrosine kinase |
|
|
ISS |
5 |
148,707,505 |
148,718,296 |
RGD:5131492 |
RGD |
| G |
Ldb3 |
LIM domain binding 3 |
|
|
ISS |
16 |
10,221,362 |
10,247,798 |
RGD:5131491 |
RGD |
| G |
Ldb3 |
LIM domain binding 3 |
|
|
ISS |
16 |
10,221,362 |
10,247,798 |
RGD:5131492 |
RGD |
| G |
Pard3 |
par-3 (partitioning defective 3) homolog (C. elegans) |
|
|
ISS |
19 |
57,015,742 |
57,603,133 |
RGD:5132275 |
RGD |
| G |
Pard6a |
par-6 (partitioning defective 6,) homolog alpha (C. elegans) |
|
|
ISS |
19 |
35,533,395 |
35,535,711 |
RGD:5132275 |
RGD |
| G |
Pard6b |
par-6 (partitioning defective 6) homolog beta (C. elegans) |
|
|
ISS |
3 |
159,230,673 |
159,251,755 |
RGD:5132275 |
RGD |
| G |
Pard6g |
par-6 partitioning defective 6 homolog gamma (C. elegans) |
|
|
ISS |
18 |
76,942,285 |
77,007,923 |
RGD:5132275 |
RGD |
| G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
|
|
ISS |
10 |
13,329,708 |
13,394,080 |
RGD:5131489 |
RGD |
| G |
Phlpp1 |
PH domain and leucine rich repeat protein phosphatase 1 |
|
|
IMP |
13 |
12,315,824 |
12,565,692 |
RGD:5131532 |
RGD |
| G |
Phlpp1 |
PH domain and leucine rich repeat protein phosphatase 1 |
|
|
ISS |
13 |
12,315,824 |
12,565,692 |
RGD:5131497 |
RGD |
| G |
Phlpp2 |
PH domain and leucine rich repeat protein phosphatase 2 |
|
|
ISS |
19 |
39,741,655 |
39,808,301 |
RGD:5131497 |
RGD |
| G |
Pick1 |
protein interacting with PRKCA 1 |
|
|
ISS |
7 |
117,213,299 |
117,232,651 |
RGD:5131491 |
RGD |
| G |
Plcb1 |
phospholipase C, beta 1 (phosphoinositide-specific) |
|
|
ISS |
3 |
122,797,718 |
123,523,675 |
RGD:5131502 |
RGD |
| G |
Plcb2 |
phospholipase C, beta 2 |
|
|
ISS |
3 |
105,203,524 |
105,223,342 |
RGD:5131502 |
RGD |
| G |
Plcb3 |
phospholipase C, beta 3 (phosphatidylinositol-specific) |
|
|
ISS |
1 |
209,628,425 |
209,643,694 |
RGD:5131502 |
RGD |
| G |
Plcb4 |
phospholipase C, beta 4 |
|
|
ISS |
3 |
123,706,313 |
124,077,381 |
RGD:5131502 |
RGD |
| G |
Prkca |
protein kinase C, alpha |
|
|
ISS |
10 |
97,367,196 |
97,638,910 |
RGD:5131489 |
RGD |
| G |
Prkcb |
protein kinase C, beta |
|
|
ISS |
1 |
181,117,512 |
181,459,856 |
RGD:5131489 |
RGD |
| G |
Prkcd |
protein kinase C, delta |
|
|
ISS |
16 |
5,954,218 |
5,975,743 |
RGD:5131489 |
RGD |
| G |
Prkce |
protein kinase C, epsilon |
|
|
ISS |
6 |
9,631,234 |
10,097,311 |
RGD:5131489 |
RGD |
| G |
Prkcg |
protein kinase C, gamma |
|
|
ISS |
1 |
64,145,749 |
64,172,712 |
RGD:5131489 |
RGD |
| G |
Prkch |
protein kinase C, eta |
|
|
IMP |
6 |
96,069,354 |
96,281,790 |
RGD:5131657 |
RGD |
| G |
Prkch |
protein kinase C, eta |
|
|
ISS |
6 |
96,069,354 |
96,281,790 |
RGD:5131489 |
RGD |
| G |
Prkci |
protein kinase C, iota |
|
|
ISS |
2 |
116,739,625 |
116,801,084 |
RGD:5131489 |
RGD |
| G |
Prkci |
protein kinase C, iota |
|
|
ISS |
2 |
116,739,625 |
116,801,084 |
RGD:5132275 |
RGD |
| G |
Prkcq |
protein kinase C, theta |
|
|
ISS |
17 |
78,486,998 |
78,566,741 |
RGD:5131489 |
RGD |
| G |
Prkcz |
protein kinase C, zeta |
|
|
IMP |
5 |
172,061,825 |
172,172,793 |
RGD:5131661 |
RGD |
| G |
Prkcz |
protein kinase C, zeta |
|
|
ISS |
5 |
172,061,825 |
172,172,793 |
RGD:5132275 |
RGD |
| G |
Prkcz |
protein kinase C, zeta |
|
|
ISS |
5 |
172,061,825 |
172,172,793 |
RGD:5131489 |
RGD |
|
|
|
Pathway Gene Annotations |
|
Disease Annotations Associated with Genes in the protein kinase C (PKC) signaling pathway
|
|
|
|
| Btk | Agammaglobulinemia , Bruton type agammaglobulinemia , Hypogammaglobulinemia and Isolated growth hormone deficiency, X-linked | |
|
| Fscn1 | Bile Duct Neoplasms , Carcinoma, Pancreatic Ductal , Cholangiocarcinoma , Common Bile Duct Neoplasms , Gallbladder Neoplasms , Neoplasm Metastasis , Pancreatic Neoplasms | | Fyn | Alzheimer Disease , Burns , Epilepsy, Temporal Lobe , Schizophrenia , Sepsis | |
| Hsp90aa1 | Breast Neoplasms , Diabetes Mellitus, Experimental , Hypertension, Portal | | Lck | Cardiomyopathy, Dilated , Conjunctivitis, Allergic , HIV Infections | | Ldb3 | MYOPATHY, MYOFIBRILLAR, 4 | |
|
|
|
|
| Phlpp1 | Prostatic Neoplasms | |
|
| Plcb1 | Cardiomegaly , EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 12 , Myocardial Infarction | |
| Plcb3 | Diabetes Mellitus, Experimental , Myocardial Infarction , Skin Ulcer | |
| Prkca | Brain Ischemia , Breast Neoplasms , Carcinoma, Intraductal, Noninfiltrating , Carcinoma, Large Cell , Cardiomegaly , Cardiomyopathy, Dilated , Endometrial Neoplasms , Heart Failure , Hypertension , Hypertrophy, Left Ventricular , Hypertrophy, Right Ventricular , Ovarian Neoplasms , Pituitary Neoplasms , Prostatic Neoplasms , Reperfusion Injury , Urinary Bladder Neoplasms | | Prkcb | Cardiomegaly , Cardiomyopathy, Dilated , Diabetes Mellitus, Experimental , Diabetic Nephropathies , Fetal Diseases , Heart Failure , Hyperalgesia , Hyperglycemia , Hypertension , Hypertrophy, Left Ventricular , Immune System Diseases , Insulin Resistance , Myocardial Reperfusion Injury , Obesity , Silicosis , Status Epilepticus | | Prkcd | Brain Ischemia , Burns , Cardiomegaly , Cardiomyopathy, Restrictive , Diabetes Mellitus, Experimental , Fatty Liver , Hyperinsulinism , Hypertension , Hypertension, Portal , Hypertrophy, Left Ventricular , Hypertrophy, Right Ventricular , Insulin Resistance , Muscular Diseases , Myocardial Ischemia , Myocardial Reperfusion Injury , Obesity , Stroke | | Prkce | Cardiomegaly , Hypertension | | Prkcg | Retinitis Pigmentosa , Spinocerebellar ataxia 14 , Spinocerebellar Ataxias | | Prkch | Cerebral Infarction | | Prkci | Breast Neoplasms , Diabetes Mellitus, Experimental , Ovarian Neoplasms | | Prkcq | Hyperammonemia , Hyperinsulinism , Insulin Resistance , Prostatic Neoplasms , Sepsis | | Prkcz | Hyperglycemia , Hypertrophy, Left Ventricular , Insulin Resistance | |
| Pancreatic Neoplasms | Fscn1 | | Agammaglobulinemia | Btk | | Ischemia | Prkca | | Skin Ulcer | Plcb3 | | Obesity | Prkcb , Prkcd | | Retinitis Pigmentosa | Prkcg | | Hyperammonemia | Prkcq | | Cholangiocarcinoma | Fscn1 | | Bile Duct Neoplasms | Fscn1 | | Cardiomegaly | Plcb1 , Prkca , Prkcb , Prkcd , Prkce | | Muscular Diseases | Prkcd | | Cardiomyopathy, Dilated | Lck , Prkca , Prkcb | | Gallbladder Neoplasms | Fscn1 | | Fatty Liver | Prkcd | | Ovarian Neoplasms | Prkca , Prkci | | Fetal Diseases | Prkcb | | Breast Neoplasms | Prkca , Prkci , Hsp90aa1 | | Spinocerebellar Ataxias | Prkcg | | Urinary Bladder Neoplasms | Prkca | | Alzheimer Disease | Fyn | | Epilepsy, Temporal Lobe | Fyn | | Hypertension | Prkca , Prkcb , Prkcd , Prkce | | Hypogammaglobulinemia and Isolated growth hormone deficiency, X-linked | Btk | | Spinocerebellar ataxia 14 | Prkcg | | Prostatic Neoplasms | Prkca , Phlpp1 , Prkcq | | Silicosis | Prkcb | | Bruton type agammaglobulinemia | Btk | | Cerebral Infarction | Prkch | | Insulin Resistance | Prkcb , Prkcz , Prkcd , Prkcq | | Hypertension, Portal | Hsp90aa1 , Prkcd | | Hyperinsulinism | Prkcd , Prkcq | | HIV Infections | Lck | | Myocardial Ischemia | Prkcd | | Immune System Diseases | Prkcb | | Burns | Fyn , Prkcd | | Carcinoma, Intraductal, Noninfiltrating | Prkca | | Cardiomyopathy, Restrictive | Prkcd | | Brain Ischemia | Prkca , Prkcd | | Common Bile Duct Neoplasms | Fscn1 | | Conjunctivitis, Allergic | Lck | | Diabetes Mellitus, Experimental | Prkcb , Plcb3 , Prkcd , Prkci , Hsp90aa1 | | Diabetic Nephropathies | Prkcb | | Heart Failure | Prkca , Prkcb | | Hyperalgesia | Prkcb | | Hyperglycemia | Prkcb , Prkcz | | Neoplasm Metastasis | Fscn1 | | Myocardial Infarction | Plcb1 , Plcb3 | | Pituitary Neoplasms | Prkca | | Schizophrenia | Fyn | | Sepsis | Fyn , Prkcq | | Status Epilepticus | Prkcb | | Reperfusion Injury | Prkca | | Myocardial Reperfusion Injury | Prkcb , Prkcd | | Endometrial Neoplasms | Prkca | | Hypertrophy, Left Ventricular | Prkca , Prkcb , Prkcz , Prkcd | | Hypertrophy, Right Ventricular | Prkca , Prkcd | | Carcinoma, Large Cell | Prkca | | Stroke | Prkcd | | Carcinoma, Pancreatic Ductal | Fscn1 | | MYOPATHY, MYOFIBRILLAR, 4 | Ldb3 | | EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 12 | Plcb1 | |
|